Antibiotics and probiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and a meta-analysis

Haonan Zhang¹, Jian Gao²*

¹ Second Clinical College, Chongqing Medical University, Chongqing, China, ² Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

* 982213482@qq.com

Abstract

Background
Modulation of the gut microbiome could favorably alter the hepatic venous pressure gradient (HVPG) in cirrhosis and portal hypertension (PH).

Aim
This meta-analysis was to evaluate the effects of microbiome-targeted therapies (MTTs) on HVPG in persons with cirrhosis and PH.

Methods
PubMed, The Cochrane Library, Embase, Web of Science and Scopus were searched for randomized clinical trials (RCTs) analyzing the effects on HVPG in people with cirrhosis who received MTTs. Clinical outcomes were pooled using RevMan5.3 software. A trial sequential analysis was applied to calculate the required information size and evaluate the credibility of the meta-analysis results.

Results
A total of six studies were included. MTTs were associated with a reduction of 1.22 mm Hg in HVPG (95% CI: -2.31, -0.14 mmHg, P = 0.03). Subgroup analysis showed a greater reduction with longer duration (-1.88 mmHg; 95% CI: -3.23, -0.53; P = 0.006). In the trial sequential analysis of HVPG reduction, the cumulative Z curve crossed the traditional significance boundary without the achievement of required information size (330).

Conclusions
MTTs may be associated with a reduction in HVPG in patients with cirrhosis and PH. Microbiome-targeted therapies merit additional large-sample studies to define the efficacy of HVPG.
Systematic review registration
PROSPERO 2020: CRD4202021609.

Introduction
Portal hypertension (PH) is a typical syndrome of cirrhosis that may result in complications such as ascites, spontaneous bacterial peritonitis, gastroesophageal variceal bleeding and other conditions [1]. Even with appropriate management, the mortality is approximately 15% to 20% among fatal complications [2]. The correlation between the increase in hepatic venous pressure gradient (HVPG) and the occurrence of PH has been well documented. HVPG > 5 mmHg indicates portal hypertension. Clinically significant portal hypertension (CSPH) was defined by a HVPG ≥ 10 mmHg [3, 4]. An observation has shown that with a reduction in HVPG > 20% from baseline or to levels below 12 mmHg, PH-related complications and mortality were significantly reduced [5, 6]. Nonselective beta-blockers (NSBBs) are the available medications for PH and show a sufficient decrease in HVPG [7, 8]. However, only a minority of patients (approximately 30% to 50%) exhibit a meaningful clinical response during NSBB therapy [8]. In addition, approximately 15% of patients have absolute or relative contraindications to therapy [9]. As a result, novel therapeutic approaches are imperative.

Gut-liver axis emphasizes the close relationship between the gut and the liver. Bacterial translocation (BT) transmits bacteria or their products from the gastrointestinal tract to normally sterile tissues [10, 11], occurring in 25% to 30% of cirrhosis patients [12]. BT results in the release of proinflammatory cytokines, such as lipopolysaccharide binding protein (LBP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and nitric oxide (NO). Proinflammatory environment finally promotes hepatocyte injury and fibrosis [13], exacerbating the hyperdynamic circulatory state and increasing hepatic vascular resistance [14–16]. As such, there is a potential for intestinal flora to be a target in PH.

Microbiome-targeted therapies (MTTs) can be divided into four categories, namely antibiotics, prebiotics, probiotics and fecal microbiota transplantation (FMT). Antibiotics such as rifaximin and norfloxacin selectively decontaminate the intestines, which could lead to HVPG changes [17, 18]. Probiotics could alter the make-up of the intestinal microbiome to decrease endotoxemia [19]. In this way, probiotic therapy might have a beneficial effect in patients with cirrhosis and PH. Given the limitation of a single type of MTT and the conflicting results, a recent meta-analysis points to a need for additional investigations.

Therefore, we aimed to conduct a meta-analysis of randomized controlled trials (RCTs) to examine the influence of microbiome-targeted therapies (MTTs) on hepatic portal venous pressure in cirrhosis with PH.

Method
We established a protocol for the review, which was registered with PROSPERO prior to commencing the study. (CRD42020216092) PRISMA checklist is provided in S1 File.

Study selection
Randomized controlled trials (RCTs) comparing MTTs against regular medication use, placebo, or a blank control in patients with cirrhosis and PH qualified for inclusion. MTTs were defined as follows: antibiotics, prebiotics, probiotics and fecal microbiota transplantation.
(FMT). Eligible RCTs met the following criteria: 1) patients were diagnosed with cirrhosis and PH; The diagnosis of cirrhosis was either liver biopsy proven or clinically suspected based on image studies and biochemical criteria. Portal hypertension was diagnosis by HVPG ≥10mm Hg or endoscopically documented large esophageal varices. 2) had an intervention group receiving MTTs; 3) had a control group receiving placebo or control medication; and 4) HVPG was evaluated before and after therapy in both the MTT and control arms. The exclusion criteria were as follows: 1) unpublished studies or studies available in abstract or letter form only; 2) HVPG measurement data were lost at baseline or endpoint, and 3) an absence of control groups.

Identification and selection of studies
We searched five electronic databases: PubMed, The Cochrane Library, Embase, Web of Science and Scopus. We used search terms such as ("cirrhosis") and ("Portal hypertension") and ("Antibiotics" or "Probiotics" or "Prebiotics" or "Fecal Bacteria Transplant"). All database searches were based on the combination of subject words and free words. Two reviewers independently investigated the titles and abstracts of studies and excluded irrelevant trials. Then each potential study was examined by two reviewers through full-text reading to assess whether the trial met the inclusion criteria. In cases of disagreement, the two reviewers reached consensus after discussion. The full electronic search strategy was listed in the S2 File.

Data extraction and study appraisal
A predesigned, standardized form was used to extract data from each included study. The information included: 1) study characteristics, including publication date, country, first author, inclusion or exclusion criteria and related details; 2) patient characteristics, such as number of patients, age, gender distribution, Child-Pugh and MELD score, and etiology of cirrhosis; 3) interventions (type and dose of MTT and duration); and 4) clinical outcomes, as previously chosen. For all articles with missing details, the corresponding authors were contacted via email to request the information. If it was not possible to obtain the data, the study was excluded from the data synthesis. We assessed all the included studies for methodological quality with the use of the Cochrane Risk of Bias tool form with the following six aspects: random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting of results and other biases.

Outcomes
The main outcome was HVPG reduction in patients treated with MTT compared with patients receiving control treatment. The additional outcomes were the plasma concentrations of BT-related markers and inflammatory cytokines. We reviewed all the included studies and chose LBP, IL-6, TNF-α and NO as the second outcomes.

Synthesis and statistical analysis
This meta-analysis was performed by RevMan5.3 software. All continuous variables are expressed as the mean ± standard deviations (SDs). When the original article did not report the mean or SD, we estimated them by the equation using the median, quartile and range. The continuous effect amounts were reported as the mean differences (MDs) and 95% confidence intervals (CIs). When different scales or large differences between numbers were used in each trial, standardized mean differences (SMDs) and 95% confidence intervals (CIs) were chosen as the combined statistics. Heterogeneity of results between studies was evaluated by chi-
squares and $I^2$ values, either chi-squares test $P < 0.10$ or $I^2$ values > 50% indicated heterogeneity, and meta-analysis was performed using a random effect. At the same time, subgroup analyses were also performed to explore the potential source of heterogeneity; otherwise, a fixed effect model was utilized.

A trial sequential analysis (TSA, version 0.9.5.10 beta) was performed to calculate the required information size (RIS) and the trial sequential monitoring boundaries. In the TSA analysis, the probabilities of a type I error ($\alpha = 0.05$) and type II error ($\beta = 0.20$) were used to calculate the RIS. The relation between the cumulative Z curve and the trial sequential monitoring boundary shows the credibility of the results.

**Results**

**Included studies**

Fig 1 shows the study selection process. We identified 3373 records according to the predesigned search strategy, of which 1128 were duplicates. Twenty-two potentially relevant manuscripts were reviewed in full-text following title and abstract screening. After full-text reviews, a total of 6 documents [20–25] met the eligibility criteria and were included in the present review. Table 1 summarizes the characteristics of the included studies.

A study [21] had three arms, and the antibiotic and probiotic treatment arms were included as intervention groups. We named them Gupta (R) and Gupta (P) respectively, compared with the third arm that used placebos (control group). Hence, there were seven comparison groups in our analysis. Two groups [21, 22] evaluated probiotics in the management of cirrhosis while five [20, 21, 23–25] groups evaluated antibiotics in the management of cirrhosis. Regrettably, no studies that used prebiotics or fecal bacteria transplantation for treatment fulfilled the inclusion criteria for our analysis. All the studies assessed PH though HVPG measurement, four [22–25] studies required patients should diagnosed with CSPH (HVPG > 10 mmHg, even more > 12 mm Hg); gastroesophageal varices were included in the remaining studies [20, 21]. Table 2 summarizes the type, dose and period of MTT. The duration varied from 28 to 90 days.

**Quality of the included studies**

Overall, the majority [20, 21, 23–25] of the included studies (83.3%) showed adequate randomization. One trial [24] adopted the random number table method to divide the groups, and four trials [20, 21, 23, 25] randomized participants by a computer-generated randomization list. Allocation concealment was considered low risk for five studies [21–25] (83.3%), but unclear for one [20], due to insufficient detail. Blinding of investigators and participants was performed in all the studies. Thus, all studies had a low risk of bias regarding blinding. All the studies reported prespecified outcome measurements. We judged one study [20] as having a high risk of bias, as it did not provide a clear explanation of withdrawals or dropouts. The risk of bias assessment is summarized in Fig 2.

**Outcomes**

HVPG. All six trials evaluated the variation in HVPG treated MTT. Compared with the control groups, six groups showed that MTTs achieved a reduction in HVPG. However, statistical significance was found in only one group [25] ($P = 0.034$).

Altogether, in the meta-analysis (Fig 3), no heterogeneity was identified ($P = 0.63$, $I^2 = 0$%), and we employed a fixed effect model. Antibiotics and probiotics were associated with a reduction in HVPG (-1.22 mmHg, 95% CI: -2.31, -0.14 mmHg; $P = 0.02$), which may indicate a HVPG decrease with MTTs.
Subgroup analysis was carried out based on the type of MTT to compare the different efficiencies between the antibiotic and probiotic groups (Fig 4). In the subgroup analysis, the effect was consistent despite different types being loaded. The probiotic group did not show a greater HVPG reduction (-1.98 mm Hg, 95% CI: -4.12, 0.16; P = 0.07) than the antibiotics group (-1.01 mm Hg, 95% CI: -2.14, 0.11 mmHg; P = 0.08), without revealing statistical significance. Perhaps this difference may become statistically significant as the sample size increases.

Subgroup analysis was also carried out in accordance with the period of therapy (Fig 5). In the subgroup analysis, the effect was different between the two groups (P = 0.03). The longer duration group showed an HVPG reduction of -1.88 mmHg (95%CI: -3.23, -0.53; P = 0.006),
which indicated a significant reduction in longer therapy. The subgroup analysis did not show heterogeneity ($P = 0.66, I^2 = 0\%$).

**Second outcomes.** Three groups [20, 24, 25] evaluated the effects of serum levels of LBP. Compared with the control groups, all showed that MTTs achieved a reduction in serum levels of LBP ($P = 0.018$, $P = 0.002$, $P < 0.01$). Five groups [20–22, 25] evaluated the effect on serum levels of IL-6. Only two [20, 24] showed statistical significance in the MTT groups ($P < 0.01$, $P = 0.026$). Serum concentrations of NO decreased markedly in the MTT group in one [20] of the four groups ($P < 0.05$).

In meta-analyses, the SMD of LBP level was -1.86 (95% CI: -3.71, 0.02; $P = 0.05$), reducing in MTT, but accompanied by high heterogeneity ($P < 0.0001$, $I^2 = 90\%$) (Fig 6A). The TNF-α level (SMD: -0.88; 95% CI: -1.62, -0.14; $P = 0.02$) was reduced significantly, followed by high heterogeneity ($P = 0.05$, $I^2 = 67\%$) (Fig 6B). The MD of the level of IL-6 was -0.59 (95% CI: -1.36, 0.19; $P = 0.14$), indicating a nonsignificant decrease with MTT and with moderate

### Table 1. The characteristics of the included studies.

| Author | Year | Country | No. of patients | NSBB Use% | Inclusion Criteria |
|--------|------|---------|----------------|-----------|--------------------|
| Albillos [20] | 2003 | Spain | 18 | NR | Cirrhosis + GEV$^a$ |
| Kemp [23] | 2009 | Australia | 16 | 56.3 | Cirrhosis + HVPG$^b$ $\geq$ 12 mmHg |
| Jayakumar [22] | 2013 | Canada | 15 | NR | Cirrhosis + HVPG $\geq$ 10 mmHg + CP$^c$ class B or C |
| Gupta [21] | 2013 | India | 94 | 100 | Cirrhosis + large GEV |
| Lim [25] | 2017 | Korea | 64 | 100 | Cirrhosis + HVPG $\geq$ 12 mmHg |
| Kimer [24] | 2017 | Denmark | 54 | 27.8 | Cirrhosis + ascites + HVPG $\geq$ 10 mmHg |

$^a$Gastroesophageal varices  
$^b$Hepatic venous pressure gradient  
$^c$Child-Pugh.

https://doi.org/10.1371/journal.pone.0273231.t001

### Table 2. The characteristics of patients in the intervention and control group (means ± standard deviation).

| Author | Arm | Treatment schedule and dose | Days | No. of patients | Males (%) | Age | Child-Pugh score | MELD score |
|--------|-----|-----------------------------|------|----------------|-----------|-----|-----------------|-----------|
| Albillos [20] | Treatment | Norfloxacin 400mg bid | 28 | 12 | NR$^a$ | NR | NR | NR |
| | Control | Placebo | 28 | 6 | NR | NR | NR | NR |
| Kemp [23] | Treatment | Norfloxacin 400mg bid | 28 | 8 | 56.3 | 59±2.4 | 6.3±0.3 | 8.7±1.1 |
| | Control | Placebo | 28 | 8 | 56.3 | 59±2.4 | 6.3±0.3 | 6.3±0.3 |
| Jayakumar [22] | Treatment | VSL#3 (3600 billion CFU) | 56 | 7 | 71.4 | 50±8.9 | 8±1.5 | 11±2.5 |
| | Control | Placebo | 56 | 8 | 87.5 | 53.5±3.7 | 8.5±1.5 | 13.5±3.6 |
| Gupta [21] | Treatment | Norfloxacin 400mg bid+ Propranolol | 60 | 31 | 77.0 | 42±14 | 8±2 | 13.3±4 |
| | Treatment | VSL#3$^b$ (900 Billion CFU$^c$) + Propranolol | 60 | 31 | 84.0 | 43±11 | 9±2 | 15.1±5 |
| | Control | Propranolol | 60 | 32 | 63.0 | 45±11 | 8±2 | 13.8±4 |
| Lim [25] | Treatment | Rifaximin 1200mg/day+ Propranolol | 90 | 16 | 93.8 | 51±9.6 | 6.9±2.2 | 10.1±3.9 |
| | Control | Propranolol | 90 | 48 | 85.4 | 48±9.7 | 7.1±1.7 | 11.4±4.1 |
| Kimer [24] | Treatment | Rifaximin 550mg bid | 28 | 36 | 86.1 | 58±8.8 | 8.6±1.3 | 12.5±4.3 |
| | Control | Placebo | 28 | 18 | 77.8 | 52±10 | 7.8±0.9 | 9.9±2.4 |

$^a$No record  
$^b$A combination of viable lyophilized bacteria  
$^c$Clonal formation unit

https://doi.org/10.1371/journal.pone.0273231.t002
heterogeneity (P = 0.01, I² = 74%) (Fig 6C). For the serum NO level, no heterogeneity was identified (P = 0.94, I² = 0%) and did not decrease significantly (SMD: -0.00; 95% CI: -0.40, 0.40; P = 1.00) (Fig 6D).

**Trial sequential analysis.** In the TSA of HVPG reduction (Fig 7), the required information size is 330. The cumulative Z curve crossed the trial sequential monitoring boundaries...
without the achievement of RIS, we think the anticipated intervention effect may have been reached.

**Discussion**

Given numerous clinical studies that identify the association between the gut microbiome and PH, PH is aggravated by hyperdynamic circulation and proinflammatory and profibrotic stimuli caused by BT [13]. Treatment targeting the gut-liver axis via modification of microbiota composition and proinflammatory have attracted increasing interest [26]. In our meta-analysis, we comprehensively conducted an assessment of the effects of MTTs on HVPG and BT-related outcomes. The results of our meta-analysis indicate that MTTs may have beneficial effects on reducing HVPG in patients with cirrhosis and portal hypertension. This reduction in HVPG might have a positive clinical impact. Similar to the study suggestions, increasing HVPG is followed by a higher risk of decompensation or death [27]. However, reducing 1–2 mmHg of portal pressure may not significantly alter the clinical outcome. Still, it underlined the potential utility of these therapies and should trigger more concerns.

When the analysis was stratified according to the type of MTT, probiotics did not reduce HVPG in cirrhosis more efficiently than antibiotic therapy, because the differences were not statistically significant. Considering the advanced effects and resistance to the long-term
antibiotic therapy [28], probiotics in cirrhosis may show more potential for clinical application with more needed validation.

Concerning the period of therapy, a longer course identified greater reduction in HVPG, suggesting that more time is required to observe the effect of MTT. This is consistent with the result showing that the chronic use of antibiotics markedly relieved the risk of complications related to PH and improved overall survival [29]. However, due to insufficient information and the various definitions of adherence, we were not able to clarify the adverse reactions in the long term.

In addition, we also estimated the nonhemodynamic effects mentioned above. Compared with the control group, LPB and TNF-α were reduced after MTT. Even with the small sample, these consequences were remarkable. Microbial products activate TLRs, which can activate to produce proinflammatory cytokines and extracellular matrix proteins, ultimately leading to hepatic fibrosis [30].

We hypothesized that MTTs affect the intestinal microbiota composition and then decrease BT, leading to endotoxemia reduction. Unfortunately, we did not further identify whether BT-related markers and proinflammatory cytokines significantly declined in the group of hemodynamic responders with MTT. This could prove our hypothesis that BT induces an inflammatory response and then exacerbates liver tissue injury and fibrosis progression, which ultimately increases portal pressure. Thus, exploring the effect of the HVPG response with MTT would be a direction for future research.

There are certain limitations in our meta-analysis. First, the number of included studies was limited, with a limited sample size. In addition, no RCTs using prebiotics or fecal bacteria transplantation for treatment fulfilled the inclusion criteria in our analysis, and most of the data coming from studies on antibiotics. Moreover, the patient population differed from study to study, and we were not able to assess the underlying possible effects of MTTs in decompensated or compensated patients. Last, it was uncertain whether such low reduction in HVPG could alter the clinical outcome.

In conclusion, our results show that microbiome-targeted therapies may reduce portal pressure in cirrhosis patients with portal hypertension. Subgroup analysis shows that with increasing duration, HVPG decreases more. At the same time, the serum levels of LBP and TNF-α, as BT markers, were also reduced after MTT. Some limitations are mentioned above, but we still

antibiotic therapy [28], probiotics in cirrhosis may show more potential for clinical application with more needed validation.

Concerning the period of therapy, a longer course identified greater reduction in HVPG, suggesting that more time is required to observe the effect of MTT. This is consistent with the result showing that the chronic use of antibiotics markedly relieved the risk of complications related to PH and improved overall survival [29]. However, due to insufficient information and the various definitions of adherence, we were not able to clarify the adverse reactions in the long term.

In addition, we also estimated the nonhemodynamic effects mentioned above. Compared with the control group, LPB and TNF-α were reduced after MTT. Even with the small sample, these consequences were remarkable. Microbial products activate TLRs, which can activate to produce proinflammatory cytokines and extracellular matrix proteins, ultimately leading to hepatic fibrosis [30].

We hypothesized that MTTs affect the intestinal microbiota composition and then decrease BT, leading to endotoxemia reduction. Unfortunately, we did not further identify whether BT-related markers and proinflammatory cytokines significantly declined in the group of hemodynamic responders with MTT. This could prove our hypothesis that BT induces an inflammatory response and then exacerbates liver tissue injury and fibrosis progression, which ultimately increases portal pressure. Thus, exploring the effect of the HVPG response with MTT would be a direction for future research.

There are certain limitations in our meta-analysis. First, the number of included studies was limited, with a limited sample size. In addition, no RCTs using prebiotics or fecal bacteria transplantation for treatment fulfilled the inclusion criteria in our analysis, and most of the data coming from studies on antibiotics. Moreover, the patient population differed from study to study, and we were not able to assess the underlying possible effects of MTTs in decompensated or compensated patients. Last, it was uncertain whether such low reduction in HVPG could alter the clinical outcome.

In conclusion, our results show that microbiome-targeted therapies may reduce portal pressure in cirrhosis patients with portal hypertension. Subgroup analysis shows that with increasing duration, HVPG decreases more. At the same time, the serum levels of LBP and TNF-α, as BT markers, were also reduced after MTT. Some limitations are mentioned above, but we still
believe our results are inspiring and worth conducting larger trials to confirm MTTs as treatments for PH, particularly given the cost-effectiveness of these treatments.

In summary, modulation of the gut microbiota through probiotics or antibiotics is considered a promising therapeutic strategy for PH. Additional research involving more cirrhosis and PH patients is required to explore the efficacy of MTTs.

### Conclusion

The result of this meta-analysis of RCTs, demonstrated that MTTs may be associated with reduction on HVPG in patients with cirrhosis and PH. Microbiome-targeted therapies merit additional large-sample studies to define the efficacy in HVPG. All data underlying this finding is fully available in S3 File.
Fig 7. Trial sequential analysis.

https://doi.org/10.1371/journal.pone.0273231.g007

Supporting information

S1 File. PRISMA 2009 checklist. (DOC)

S2 File. The full electronic search strategy. (DOCX)

S3 File. Data set. (XLSX)

Author Contributions

Data curation: Haonan Zhang.

Formal analysis: Haonan Zhang, Jian Gao.

Investigation: Haonan Zhang.

Methodology: Haonan Zhang.

Project administration: Haonan Zhang, Jian Gao.

Resources: Haonan Zhang.

Software: Haonan Zhang.

Visualization: Haonan Zhang, Jian Gao.
Writing – original draft: Haonan Zhang.
Writing – review & editing: Haonan Zhang, Jian Gao.

References

1. Simonetto DA, Liu M, Kamath PS. Portal Hypertension and Related Complications: Diagnosis and Management. Mayo Clin Proc 2019; 94:714–726. https://doi.org/10.1016/j.mayocp.2018.12.020 PMID: 30947834

2. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017; 65:310–335. https://doi.org/10.1002/hep.28906 PMID: 27786365

3. Qi X, Berzigotti A, Cardenas A, Sarin SK. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol 2018; 3:708–719. https://doi.org/10.1016/S2468-1253(18)30232-2 PMID: 30215362

4. Gunaratne LS, Rajapaksha H, Shackell N. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics. World J Gastroenterol 2020; 26:6111–6140. https://doi.org/10.3748/wjg.v26.i40.6111 PMID: 33177789

5. Kerbert AJ, Chiang FW, van der Werf M, Stijnen T, Slingerland H, et al. Hemodynamic response to primary prophylactic therapy with nonselective beta-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis: a meta-analysis. Eur J Gastroenterol Hepatol 2017; 29:380–387.

6. Turco L, Villanueva C, La Mura V, Garcia-Pagán JC, Reiberger T, et al. Lowering Portal Pressure Improves Outcomes of Patients with Cirrhosis, With or Without Ascites: A Meta-Analysis. Clin Gastroenterol Hepatol 2020; 18:313–327 e316. https://doi.org/10.1016/j.cgh.2019.05.050 PMID: 31176013

7. Selicean S, Wang C, Guixé-Muntet S, Stefanescu H, Kawada N, et al. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatol Int 2021; 15:36–50. https://doi.org/10.1007/s12072-021-10135-4 PMID: 33544313

8. Sharma M, Singh S, Desai V, Shah VH, Kamath PS, Murad MH, et al. Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding: A Systematic Review and Network Meta-analysis. Hepatology 2019; 69:1657–1675. https://doi.org/10.1002/hep.30220 PMID: 30215369

9. Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, et al. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst Rev 2018; 10:CD011510. https://doi.org/10.1002/14651858.CD011510.pub2 PMID: 30372514

10. Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018; 15:397–411. https://doi.org/10.1038/s41575-018-0011-z PMID: 29748586

11. Mandato C, Delli Bovi AP, Vajro P. The gut-liver axis as a target of liver disease management. Hepatobiliary Surg Nutr 2021; 10:100–102. https://doi.org/10.21037/hbsn.2020.03.27 PMID: 33575294

12. Ponziani FR, Zocco MA, Cerrito L, Gasbarrini A, Pompili M. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Rev Gastroenterol Hepatol 2018; 12:641–656. https://doi.org/10.1080/17474124.2018.1481747 PMID: 29806487

13. Simbrunner B, Mandonfer M, Trauner M, Reiberger T. Gut-liver axis signaling in portal hypertension. World J Gastroenterol 2019; 25:5897–5917. https://doi.org/10.3748/wjg.v25.i39.5897 PMID: 31660028

14. Agiasotelli D, Alexopoulou A, Vasilieva L, Hadziyannis E, Goukos D, et al. High serum lipopolysaccharide binding protein is associated with increased mortality in patients with decompensated cirrhosis. Liver Int 2017; 37:576–582. https://doi.org/10.1111/liv.13264 PMID: 27712029

15. Arroyo V, Angeli P, Moreau R. The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol 2021; 74:670–685. https://doi.org/10.1016/j.jhep.2020.11.048 PMID: 33301825

16. Labenz C, Toenge G, Huber Y, Nagel M, Marquardt JU, et al. Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy. Aliment Pharmacol Ther 2019; 50:1112–1119. https://doi.org/10.1111/apt.15515 PMID: 31537473

17. Hu L, Su L, Dong Z, Wu Y, Lv Y, et al. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model. J Mol Med (Berl) 2019; 97:423–434. https://doi.org/10.1007/s00109-019-01746-4 PMID: 30721324
18. Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003; 139:186–193. https://doi.org/10.7326/0003-4819-139-3-200308050-00008 PMID: 12899586

19. Grylls A, Seidler K, Neil J. Link between microbiota and hypertension: Focus on LPS/TLR4 pathway in endothelial dysfunction and vascular inflammation, and therapeutic implication of probiotics. Biomed Pharmacother 2021; 137:111334. https://doi.org/10.1016/j.biopha.2021.111334 PMID: 33556874

20. Albillos A, de la Hera A, Gonzalez M, Moya JL, Calleja JL, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37:208–217. https://doi.org/10.1053/jhep.2003.50038 PMID: 12500206

21. Gupta N, Kumar A, Sharma P, Garg V, Sharma BC, et al. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. Liver Int 2013; 33:1148–1157. https://doi.org/10.1111/liv.12172 PMID: 23601333

22. Jayakumar S, Carbonneau M, Hotte N, Befus AD, St Laurent C, et al. VSL#3 (R) probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis. Liver Int 2013; 33:1470–1477.

23. Kemp W, Colman J, Thompson K, Madan A, Vincent M, et al. Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial. Liver Int 2009; 29:427–433. https://doi.org/10.1111/j.1478-3231.2008.01850.x PMID: 18673434

24. Kimer N, Pedersen JS, Busk TM, Gluud LL, Hobolth L, et al. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. Hepatology 2017; 65:592–603. https://doi.org/10.1002/hep.28898 PMID: 27775818

25. Lim YL, Kim MY, Jang YO, Baik SK, Kwon SO. Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study. Gut Liver 2017; 11:702–710. https://doi.org/10.5009/gnl16478 PMID: 28651304

26. Baffy G. Potential mechanisms linking gut microbiota and portal hypertension. Liver Int 2019; 39:598–609. https://doi.org/10.1111/liv.13986 PMID: 30312513

27. de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63:743–752. https://doi.org/10.1016/j.jhep.2015.05.022 PMID: 26047908

28. Bejar-Serrano S, Del Pozo P, Fernandez-de la Varga M, Benlloch S. Multidrug-resistant bacterial infections in patients with liver cirrhosis in a tertiary referral hospital. Gastroenterol Hepatol 2019; 42:228–238.

29. Habib S, Patel N, Yarlagadda S, Hsu CH, Patel S, et al. Safety and efficacy of antibiotics among acutely decompensated cirrhosis patients. J Gastroenterol Hepatol 2018; 33:1882–1888. https://doi.org/10.1111/jgh.14267 PMID: 29697158

30. Fan Y, Li Y, Chu Y, Liu J, Cui L, Zhang D. Toll-Like Receptors Recognize Intestinal Microbes in Liver Cirrhosis. Front Immunol 2021; 12:608498. https://doi.org/10.3389/fimmu.2021.608498 PMID: 33708204